The aim of this study was to investigate whether selected growth factors (VEGF, FGF), lectins (Galectin-1, Galectin-3), protein (Fascin), or cytokine (TNF-α) measured in the serum of patients with disseminated endocrine neoplasms could serve as potential biomarkers for active disease or tumor recurrence. This evidence concerns the gene FSCN1 and endocrine gland neoplasm.